DK4114826T3 - Krystallinske former af en farmaceutisk forbindelse - Google Patents
Krystallinske former af en farmaceutisk forbindelse Download PDFInfo
- Publication number
- DK4114826T3 DK4114826T3 DK21798287.5T DK21798287T DK4114826T3 DK 4114826 T3 DK4114826 T3 DK 4114826T3 DK 21798287 T DK21798287 T DK 21798287T DK 4114826 T3 DK4114826 T3 DK 4114826T3
- Authority
- DK
- Denmark
- Prior art keywords
- crystalline forms
- pharmaceutical compound
- pharmaceutical
- compound
- crystalline
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20199934.9A EP3978474A1 (en) | 2020-10-02 | 2020-10-02 | Crystalline forms of a pharmaceutical compound |
| PCT/EP2021/077100 WO2022069709A1 (en) | 2020-10-02 | 2021-10-01 | Crystalline forms of a pharmaceutical compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4114826T3 true DK4114826T3 (da) | 2023-11-13 |
Family
ID=72744696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21798287.5T DK4114826T3 (da) | 2020-10-02 | 2021-10-01 | Krystallinske former af en farmaceutisk forbindelse |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12116344B2 (da) |
| EP (3) | EP3978474A1 (da) |
| JP (2) | JP7809655B2 (da) |
| KR (2) | KR20240056628A (da) |
| CN (1) | CN116390910A (da) |
| AU (2) | AU2021353055B2 (da) |
| BR (2) | BR122022018214A2 (da) |
| CA (1) | CA3193939C (da) |
| CL (1) | CL2023000943A1 (da) |
| DK (1) | DK4114826T3 (da) |
| ES (1) | ES2964105T3 (da) |
| FI (1) | FI4114826T3 (da) |
| IL (2) | IL316634A (da) |
| MA (1) | MA58885B1 (da) |
| MX (1) | MX2023003618A (da) |
| PE (1) | PE20240138A1 (da) |
| TW (1) | TWI912383B (da) |
| WO (1) | WO2022069709A1 (da) |
| ZA (1) | ZA202310184B (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3978474A1 (en) * | 2020-10-02 | 2022-04-06 | Azafaros B.V. | Crystalline forms of a pharmaceutical compound |
| IL314212A (en) * | 2022-01-10 | 2024-09-01 | Azafaros B V | Treatment of GM2 gangliosidosis |
| EP4209215A1 (en) * | 2022-01-10 | 2023-07-12 | Azafaros B.V. | Treatment of gm2 gangliosidosis |
| AU2025214578A1 (en) | 2024-02-01 | 2026-08-13 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
| EP4595964A1 (en) | 2024-02-01 | 2025-08-06 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
| EP4678174A1 (en) * | 2024-07-11 | 2026-01-14 | Azafaros B.V. | Nizubaglustat for use in the treatment of lysosomal storage disorders |
| WO2026013261A1 (en) * | 2024-07-11 | 2026-01-15 | Azafaros B.V. | Nizubaglustat for use in the treatment of lysosomal storage disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2895490T3 (es) | 2014-03-27 | 2022-02-21 | Acad Medisch Ct | Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa |
| US20190195897A1 (en) * | 2015-06-24 | 2019-06-27 | Universiteit Leiden | Glycosylated metabolites |
| EP3978474A1 (en) * | 2020-10-02 | 2022-04-06 | Azafaros B.V. | Crystalline forms of a pharmaceutical compound |
-
2020
- 2020-10-02 EP EP20199934.9A patent/EP3978474A1/en not_active Withdrawn
-
2021
- 2021-10-01 KR KR1020247012671A patent/KR20240056628A/ko active Pending
- 2021-10-01 EP EP23191550.5A patent/EP4295847A3/en active Pending
- 2021-10-01 FI FIEP21798287.5T patent/FI4114826T3/fi active
- 2021-10-01 DK DK21798287.5T patent/DK4114826T3/da active
- 2021-10-01 BR BR122022018214-3A patent/BR122022018214A2/pt not_active Application Discontinuation
- 2021-10-01 TW TW110136766A patent/TWI912383B/zh active
- 2021-10-01 MX MX2023003618A patent/MX2023003618A/es unknown
- 2021-10-01 CA CA3193939A patent/CA3193939C/en active Active
- 2021-10-01 CN CN202180067242.0A patent/CN116390910A/zh active Pending
- 2021-10-01 KR KR1020237014953A patent/KR102659466B1/ko active Active
- 2021-10-01 WO PCT/EP2021/077100 patent/WO2022069709A1/en not_active Ceased
- 2021-10-01 EP EP21798287.5A patent/EP4114826B1/en active Active
- 2021-10-01 US US18/029,842 patent/US12116344B2/en active Active
- 2021-10-01 PE PE2023001212A patent/PE20240138A1/es unknown
- 2021-10-01 AU AU2021353055A patent/AU2021353055B2/en active Active
- 2021-10-01 JP JP2022577645A patent/JP7809655B2/ja active Active
- 2021-10-01 MA MA58885A patent/MA58885B1/fr unknown
- 2021-10-01 ES ES21798287T patent/ES2964105T3/es active Active
- 2021-10-01 IL IL316634A patent/IL316634A/en unknown
- 2021-10-01 BR BR112022018020-9A patent/BR112022018020B1/pt active IP Right Grant
- 2021-10-01 IL IL301882A patent/IL301882B2/en unknown
-
2022
- 2022-12-20 AU AU2022291486A patent/AU2022291486B2/en active Active
-
2023
- 2023-03-30 CL CL2023000943A patent/CL2023000943A1/es unknown
- 2023-10-30 ZA ZA2023/10184A patent/ZA202310184B/en unknown
-
2024
- 2024-02-02 JP JP2024015037A patent/JP2024054192A/ja active Pending
- 2024-08-30 US US18/821,921 patent/US20250059137A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3972960T3 (da) | Krystallinske former af en btk-hæmmer | |
| IL304497A (en) | Crystalline forms of a pyrrolopyridine-aniline compound | |
| DK4313945T3 (da) | Krystallinsk hydrobromidsalt af 5-MeO-DMT | |
| IL310264A (en) | Annulated pyridazine compound | |
| DK3880670T3 (da) | Forbedret syntese af nøglemellemprodukt af kras-g12c-hæmmerforbindelse | |
| DK4214202T3 (da) | Faste former af en cdk4-hæmmer | |
| DK3999038T3 (da) | Orale formuleringer af en kardial sarcomer-inhibitor | |
| EP3619208C0 (en) | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | |
| EP4293025C0 (en) | COMPOSED WITH 4-AMINOQUINAZOLINE | |
| EP4146799A4 (en) | CRYSTALLINE ANALOGUES OF DIMETHYLTRYPTAMINE | |
| IL286218A (en) | Solid state forms of ripretinib | |
| EP4277621A4 (en) | CRYSTALLINE BUFOTENIDINE COMPOUNDS | |
| DK3826982T3 (da) | Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer | |
| EP4204551C0 (en) | XYLOGLUCANASE VARIANTS OF FAMILY 44 | |
| PL3848361T3 (pl) | Sposób wytwarzania związku tetracyklicznego | |
| DK3749673T3 (da) | Krystallinsk form af bictegravir-natrium | |
| EP4291180C0 (en) | CRYSTALLINE COMPOUNDS OF 5-METHOXY-DIPROPYL TRYPTAMINE | |
| DK3847175T3 (da) | Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor | |
| IL313405A (en) | Synthesis of glufosinate using a hydantoinase-based process | |
| GB202005114D0 (en) | Crystalline Forms of a Pharmaceutical Compound | |
| DK3459538T3 (da) | Krystallinske salte af et dextroamfetamin-prodrug | |
| DK4132909T3 (da) | Organiske syreadditionssalte af S-pindolol | |
| DK4441028T3 (da) | Salt af S-oxprenolol | |
| EP4169915A4 (en) | CRYSTALLINE FORM OF COMPOUND | |
| EP3919493A4 (en) | CRYSTAL OF A DIARYLTHIOHYDANTOIN COMPOUND |